Novo Nordisk A/S (NVO) 43.80 $NVO
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
PR Newswire - Wed Dec 24, 4:41PM CST
Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI greater-than or equal to 30 kg/m2) or who are overweight (BMI greater-than or equal to 27 kg/m2) in the presence of at least one weight-related comorbid condition.
NVO: 43.80 (+1.08)
Novo Nordisk Set to Possibly Pullback After Yesterday's Rally of 2.53%
Comtex SmarTrend(R) - Wed Dec 24, 4:18PM CST
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $43.51 to a high of $44.32. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $44.28 on volume of 700,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 43.80 (+1.08)
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), ARNA: 3.57 (-0.01)
Heard on the Street: New Research on American Airlines, Novo Nordisk, Novartis, DIRECTV and Sony
PR Newswire - Wed Dec 24, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including American Airlines (NASDAQ: AAL), Novo Nordisk (NYSE: NVO), Novartis (NYSE: NVS), DIRECTV (NASDAQ: DTV), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVO: 43.80 (+1.08), DTV: 86.82 (-0.05), SNE: 21.32 (+0.46), AAL: 51.43 (+1.22), NVS: 93.91 (+0.66)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.99 (+0.67), OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Novo Nordisk receives FDA approval for Saxenda(R) for the treatment of obesity
GlobeNewswire - Tue Dec 23, 2:48PM CST
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda(liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m) or who are overweight (BMI =>27 kg/m) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.
NVO: 43.80 (+1.08)
This May Be the Fastest-Growing Big Pharma Next Year (Hint: It Isn't Johnson & Johnson)
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 6:03AM CST
Johnson & Johnson is one of the globe's biggest drugmakers. It markets a slate of billion-dollar blockbuster therapies that cuts across autoimmune disease, oncology, and infectious disease. Thanks to J&J's successful research and...
JNJ: 104.59 (+0.31), NVO: 43.80 (+1.08)
Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:10PM CST
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded use.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), ABBV: 66.21 (+1.86)
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)
Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Dec 22, 7:01AM CST
On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
NVO: 43.80 (+1.08)
Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies
PR Newswire - Thu Dec 18, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has entered into a collaboration and licensing agreement with Novo Nordisk to jointly discover novel biologic drug candidates for an undisclosed target by combining multiple Xencor XmAb® technologies, including bispecific and immune inhibitor technologies. Xencor is eligible to receive up to approximately $175 million in upfront payments, research support, and pre-clinical and clinical development, regulatory and sales milestones, in addition to future royalties.
NVO: 43.80 (+1.08), XNCR: 16.83 (+0.77)
Another Take On Why Timing The Market Does Not Work
David Hunkar - Seeking Alpha - Wed Dec 17, 7:57AM CST
Originally published on October 21, 2014 Investors should invest in stocks for the long term and not engage in short-term trading. Long-term is measured in years and can be considered as at least five years. Trying to time the market is not a good...
BUD: 115.51 (+0.09), NVO: 43.80 (+1.08), TOT: 53.05 (-0.29), NVS: 93.91 (+0.66)
Australian Diabetes Management Devices Market 2007 - 2020
M2 - Tue Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5t2tt/australian) has announced the addition of the "Australian Diabetes Management Devices Market, 2007 - 2020" report to their offering. The Australian Diabetes Management and Diabetes Diagnostic Devices market jumped by $46 million between 2005 and 2013 The market comprises continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps. The growth is driven by the high prevalence of diabetes, acceptance and proliferation of advanced patient compliant technologies, increased reimbursement of devices and government subsidy on consumables. Especially, continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) and manual insulin delivery products exhibited significant market growth. The prevalence of diabetes in Australia has skyrocketed three times to 4.2% over the last 25 years. Around 1 million people in country suffer from diabetes and around 2 million have pre-diabetes. Of these, 11% have type 1 diabetes, 87% have type 2 diabetes and 2% women have gestational diabetes. We estimate that approximately 3.4 million citizens will suffer from diabetes by 2030. This high progression rates in diabetes can be attributed to the growth in elderly population, increased life expectancy, obesity, sedentary life style, unhealthy diet and high stress levels. Further, factors like smoking and physical inactivity have led to increased prevalence of both the types of diabetes in young people. Key Topics Covered: 1. Charts & Tables 2. Australia Market for Diabetes Management Devices (2007-2020) 3. Australia Market for Blood Glucose Monitoring Systems (2007-2020) 4. Australia Market for Insulin Delivery Devices (2007-2020) 5. Recent Global Developments 6. Company and Product Profiles ARKRAY Inc. Abbott Laboratories Animas Corporation Bayer HealthCare AG Becton Dickinson and Company Eli Lilly and Company F. Hoffmann-La Roche AG LifeScan Inc. Medtronic Inc. Novo Nordisk A/S Sanofi S.A. Smiths Medical Terumo Corporation For more information visit http://www.researchandmarkets.com/research/k5t2tt/australian
ABT: 45.70 (-0.02), NVO: 43.80 (+1.08), MDT: 74.08 (+0.31), LLY: 70.16 (+0.42)
Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin
M2 - Tue Dec 16, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/383pkw/asia_pacific) has announced the addition of the "Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin" report to their offering. The industry research publication titled Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin' presents a comprehensive analysis of market size by value of major types of insulin consumed in Asia Pacific region. The report entails the market share analysis of major insulin brands in premix insulin, long acting and rapid acting insulin category and company profiles of major players in the insulin market in India, China and Japan. The future analysis has also been discussed in each market. Key Topics Covered: 1. Asia Pacific Insulin Market Introduction 2. India Insulin Market Introduction 3. China Insulin Market Introduction 4. Japan Insulin Market Introduction 5. Appendix Companies Mentioned - BJ Ganli Pharmaceuticals - Biocon Limited - Eli Lilly and Company - Eli Lilly and Company India Private Limited - Novo Nordisk (China) Pharmaceutical Company Limited - Novo Nordisk India Private Limited - Sanofi China - Sanofi India Limited - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/38...ia_pacific
NVO: 43.80 (+1.08), LLY: 70.16 (+0.42)
Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series
PR Newswire - Fri Dec 12, 8:00AM CST
Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams (CGRT), today announced a multi-year extension of their partnership, that will renew Novo Nordisk as the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the Verizon IndyCar Series.
NVO: 43.80 (+1.08)
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
PR Newswire - Wed Dec 24, 4:41PM CST
Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI greater-than or equal to 30 kg/m2) or who are overweight (BMI greater-than or equal to 27 kg/m2) in the presence of at least one weight-related comorbid condition.
NVO: 43.80 (+1.08)
Novo Nordisk Set to Possibly Pullback After Yesterday's Rally of 2.53%
Comtex SmarTrend(R) - Wed Dec 24, 4:18PM CST
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $43.51 to a high of $44.32. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $44.28 on volume of 700,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 43.80 (+1.08)
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), ARNA: 3.57 (-0.01)
Heard on the Street: New Research on American Airlines, Novo Nordisk, Novartis, DIRECTV and Sony
PR Newswire - Wed Dec 24, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including American Airlines (NASDAQ: AAL), Novo Nordisk (NYSE: NVO), Novartis (NYSE: NVS), DIRECTV (NASDAQ: DTV), and Sony (NYSE: SNE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVO: 43.80 (+1.08), DTV: 86.82 (-0.05), SNE: 21.32 (+0.46), AAL: 51.43 (+1.22), NVS: 93.91 (+0.66)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.99 (+0.67), OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Novo Nordisk receives FDA approval for Saxenda(R) for the treatment of obesity
GlobeNewswire - Tue Dec 23, 2:48PM CST
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda(liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI =>30 kg/m) or who are overweight (BMI =>27 kg/m) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease.
NVO: 43.80 (+1.08)
This May Be the Fastest-Growing Big Pharma Next Year (Hint: It Isn't Johnson & Johnson)
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 6:03AM CST
Johnson & Johnson is one of the globe's biggest drugmakers. It markets a slate of billion-dollar blockbuster therapies that cuts across autoimmune disease, oncology, and infectious disease. Thanks to J&J's successful research and...
JNJ: 104.59 (+0.31), NVO: 43.80 (+1.08)
Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:10PM CST
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded use.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), ABBV: 66.21 (+1.86)
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)
Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Dec 22, 7:01AM CST
On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
NVO: 43.80 (+1.08)
Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies
PR Newswire - Thu Dec 18, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has entered into a collaboration and licensing agreement with Novo Nordisk to jointly discover novel biologic drug candidates for an undisclosed target by combining multiple Xencor XmAb® technologies, including bispecific and immune inhibitor technologies. Xencor is eligible to receive up to approximately $175 million in upfront payments, research support, and pre-clinical and clinical development, regulatory and sales milestones, in addition to future royalties.
NVO: 43.80 (+1.08), XNCR: 16.83 (+0.77)
Another Take On Why Timing The Market Does Not Work
David Hunkar - Seeking Alpha - Wed Dec 17, 7:57AM CST
Originally published on October 21, 2014 Investors should invest in stocks for the long term and not engage in short-term trading. Long-term is measured in years and can be considered as at least five years. Trying to time the market is not a good...
BUD: 115.51 (+0.09), NVO: 43.80 (+1.08), TOT: 53.05 (-0.29), NVS: 93.91 (+0.66)
Australian Diabetes Management Devices Market 2007 - 2020
M2 - Tue Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5t2tt/australian) has announced the addition of the "Australian Diabetes Management Devices Market, 2007 - 2020" report to their offering. The Australian Diabetes Management and Diabetes Diagnostic Devices market jumped by $46 million between 2005 and 2013 The market comprises continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps. The growth is driven by the high prevalence of diabetes, acceptance and proliferation of advanced patient compliant technologies, increased reimbursement of devices and government subsidy on consumables. Especially, continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) and manual insulin delivery products exhibited significant market growth. The prevalence of diabetes in Australia has skyrocketed three times to 4.2% over the last 25 years. Around 1 million people in country suffer from diabetes and around 2 million have pre-diabetes. Of these, 11% have type 1 diabetes, 87% have type 2 diabetes and 2% women have gestational diabetes. We estimate that approximately 3.4 million citizens will suffer from diabetes by 2030. This high progression rates in diabetes can be attributed to the growth in elderly population, increased life expectancy, obesity, sedentary life style, unhealthy diet and high stress levels. Further, factors like smoking and physical inactivity have led to increased prevalence of both the types of diabetes in young people. Key Topics Covered: 1. Charts & Tables 2. Australia Market for Diabetes Management Devices (2007-2020) 3. Australia Market for Blood Glucose Monitoring Systems (2007-2020) 4. Australia Market for Insulin Delivery Devices (2007-2020) 5. Recent Global Developments 6. Company and Product Profiles ARKRAY Inc. Abbott Laboratories Animas Corporation Bayer HealthCare AG Becton Dickinson and Company Eli Lilly and Company F. Hoffmann-La Roche AG LifeScan Inc. Medtronic Inc. Novo Nordisk A/S Sanofi S.A. Smiths Medical Terumo Corporation For more information visit http://www.researchandmarkets.com/research/k5t2tt/australian
ABT: 45.70 (-0.02), NVO: 43.80 (+1.08), MDT: 74.08 (+0.31), LLY: 70.16 (+0.42)
Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin
M2 - Tue Dec 16, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/383pkw/asia_pacific) has announced the addition of the "Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin" report to their offering. The industry research publication titled Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin' presents a comprehensive analysis of market size by value of major types of insulin consumed in Asia Pacific region. The report entails the market share analysis of major insulin brands in premix insulin, long acting and rapid acting insulin category and company profiles of major players in the insulin market in India, China and Japan. The future analysis has also been discussed in each market. Key Topics Covered: 1. Asia Pacific Insulin Market Introduction 2. India Insulin Market Introduction 3. China Insulin Market Introduction 4. Japan Insulin Market Introduction 5. Appendix Companies Mentioned - BJ Ganli Pharmaceuticals - Biocon Limited - Eli Lilly and Company - Eli Lilly and Company India Private Limited - Novo Nordisk (China) Pharmaceutical Company Limited - Novo Nordisk India Private Limited - Sanofi China - Sanofi India Limited - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/38...ia_pacific
NVO: 43.80 (+1.08), LLY: 70.16 (+0.42)
Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series
PR Newswire - Fri Dec 12, 8:00AM CST
Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams (CGRT), today announced a multi-year extension of their partnership, that will renew Novo Nordisk as the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the Verizon IndyCar Series.
NVO: 43.80 (+1.08)
